Concepedia

ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update

Nathan I. Cherny, Dario Trapani, M. Galotti, M. Saar, Gracemarie Bricalli, Felipe Roitberg, Bishal Gyawali, Giuseppe Curigliano, Jean‐Yves Blay, Kathryn E. Meier,

Annals of Oncology · 2025 · 21 citations · 9 references

DOIFull text

Open access

Concepts

References

9

Global Health Observatory Data Repository

Emily Vardell · Medical Reference Services Quarterly · 2020 · 1.6K citations

, , +13

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

Nathan I. Cherny, Richard Sullivan, Urania Dafni et al. · Annals of Oncology · 2015 · 807 citations · Full text

, , +15

ESMO-Magnitude of Clinical Benefit Scale version 1.1

Nathan I. Cherny, Urania Dafni, Jan Bogaerts et al. · Annals of Oncology · 2017 · 648 citations · Full text

, , +6

ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe

Nathan I. Cherny, Richard Sullivan, Julie Torode et al. · Annals of Oncology · 2016 · 172 citations · Full text

, , +16

Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey

Adam Fundytus, Manju Sengar, Dorothy Lombe et al. · The Lancet Oncology · 2021 · 171 citations · Full text

, , +13